Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Soligenix Inc SNGX

Healthcare Biotechnology
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Recent & Breaking News (NDAQ:SNGX)

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

PR Newswire 10 days ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Accesswire November 15, 2024

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

PR Newswire November 14, 2024

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

PR Newswire November 8, 2024

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

GlobeNewswire October 24, 2024

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

PR Newswire October 22, 2024

Soligenix Invited to Present at Upcoming Investor Conferences

PR Newswire October 16, 2024

HyBryte(TM) Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

PR Newswire October 7, 2024

Soligenix Announces Partnership with Sterling Pharma Solutions

PR Newswire October 3, 2024

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire September 20, 2024

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

PR Newswire September 16, 2024

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

PR Newswire September 3, 2024

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire August 16, 2024

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

PR Newswire August 9, 2024

Expanded HyBryte(TM) Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

PR Newswire July 9, 2024

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire June 25, 2024

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

PR Newswire June 14, 2024

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire June 7, 2024

Soligenix Announces Reverse Stock Split

PR Newswire May 31, 2024

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

PR Newswire May 29, 2024